This report describes the global market size of Non-alcoholic Steatohepatitis Drug from 2019 to 2023 and its CAGR from 2019 to 2023, and also forecasts its market size to the end of 2029 and its CAGR from 2024 to 2029.
For the geography segment; regional supply, demand, major players, and price is presented from 2019 to 2029.
For the competitor segment, the report includes global key players of Non-alcoholic Steatohepatitis Drug as well as some small players.
Historical Data: from 2019 to 2023
Forecast Data: from 2024 to 2029
This product will be delivered within 1-3 business days.
For the geography segment; regional supply, demand, major players, and price is presented from 2019 to 2029.
This report covers the following regions:
- North America
- South America
- Asia & Pacific
- Europe
- MEA
For the competitor segment, the report includes global key players of Non-alcoholic Steatohepatitis Drug as well as some small players.
The information for each competitor includes:
- Company Profile
- Business Information
- SWOT Analysis
- Revenue, Gross Margin and Market Share
Companies Covered
- AstraZeneca PLC
- Eli Lilly
- Gilead Sciences
- Merck & Co. Inc.
- Novo Nordisk
- Novartis AG
- Pfizer Inc.
- Roche Holding AG
- Enanta Pharmaceuticals Inc.
- Ionis Pharmceuticals Inc.
Historical Data: from 2019 to 2023
Forecast Data: from 2024 to 2029
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1 Executive SummaryChapter 2 Abbreviation and Acronyms
Chapter 3 Preface
Chapter 4 Market Landscape
Chapter 5 Market Trend Analysis
Chapter 6 Industry Chain Analysis
Chapter 7 Latest Market Dynamics
Chapter 8 Historical and Forecast Non-Alcoholic Steatohepatitis Drug Market in North America (2019-2029)
Chapter 9 Historical and Forecast Non-Alcoholic Steatohepatitis Drug Market in South America (2019-2029)
Chapter 10 Historical and Forecast Non-Alcoholic Steatohepatitis Drug Market in Asia & Pacific (2019-2029)
Chapter 11 Historical and Forecast Non-Alcoholic Steatohepatitis Drug Market in Europe (2019-2029)
Chapter 12 Historical and Forecast Non-Alcoholic Steatohepatitis Drug Market in MEA (2019-2029)
Chapter 13 Summary For Global Non-Alcoholic Steatohepatitis Drug Market (2019-2024)
Chapter 14 Global Non-Alcoholic Steatohepatitis Drug Market Forecast (2024-2029)
Chapter 15 Analysis of Global Key Vendors
List of Tables and Figures
Companies Mentioned
- AstraZeneca PLC
- Eli Lilly
- Gilead Sciences
- Merck & Co. Inc.
- Novo Nordisk
- Novartis AG
- Pfizer Inc.
- Roche Holding AG
- Enanta Pharmaceuticals Inc.
- Ionis Pharmceuticals Inc.
- NGM Biopharmaceuticals Inc.
- Pliant Therapeutics
- Inc.
- Terns Pharmaceuticals Inc.
- 89bio Inc.